Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
$4.37
$4.92
$2.60
$11.99
$4.24M1.5526,396 shs35,704 shs
Celcuity, Inc. stock logo
CELC
Celcuity
$13.50
-0.9%
$11.71
$7.58
$19.77
$511.06M0.45275,499 shs19,210 shs
Centogene stock logo
CNTG
Centogene
$0.17
$0.25
$1.53
$8.80M-0.67150,868 shs8.36 million shs
DermTech, Inc. stock logo
DMTK
DermTech
$0.19
$0.09
$3.90
$3.29M2.481.07 million shs3.66 million shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.32
$0.25
$1.20
$17.03M1.19170,636 shs4.12 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
0.00%0.00%0.00%0.00%0.00%
Celcuity, Inc. stock logo
CELC
Celcuity
+0.81%-1.23%+5.42%+47.56%-19.17%
Centogene stock logo
CNTG
Centogene
0.00%0.00%0.00%0.00%-68.61%
DermTech, Inc. stock logo
DMTK
DermTech
0.00%0.00%0.00%0.00%+6.45%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%+4.17%-69.91%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
N/AN/AN/AN/AN/AN/AN/AN/A
Celcuity, Inc. stock logo
CELC
Celcuity
2.3048 of 5 stars
3.61.00.00.02.72.50.0
Centogene stock logo
CNTG
Centogene
N/AN/AN/AN/AN/AN/AN/AN/A
DermTech, Inc. stock logo
DMTK
DermTech
N/AN/AN/AN/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
0.00
N/AN/AN/A
Celcuity, Inc. stock logo
CELC
Celcuity
3.17
Buy$28.40108.52% Upside
Centogene stock logo
CNTG
Centogene
0.00
N/AN/AN/A
DermTech, Inc. stock logo
DMTK
DermTech
0.00
N/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest DMTK, ANPC, ENZ, CELC, and CNTG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
6/30/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00
5/19/2025
Celcuity, Inc. stock logo
CELC
Celcuity
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
5/15/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
4/11/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
$1.75M2.42N/AN/A($1.41) per share-3.10
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/A$3.11 per shareN/A
Centogene stock logo
CNTG
Centogene
$48.54M0.00N/AN/A($1.01) per share0.00
DermTech, Inc. stock logo
DMTK
DermTech
$15.66M0.00N/AN/A$1.67 per share0.00
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
-$14.77MN/A0.00N/AN/AN/AN/AN/A
Celcuity, Inc. stock logo
CELC
Celcuity
-$111.78M-$3.03N/AN/AN/AN/A-96.21%-49.44%8/13/2025 (Estimated)
Centogene stock logo
CNTG
Centogene
-$38.58MN/A0.00N/AN/AN/AN/AN/AN/A
DermTech, Inc. stock logo
DMTK
DermTech
-$100.89M-$2.70N/AN/AN/A-572.19%-138.79%-68.96%N/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%N/A

Latest DMTK, ANPC, ENZ, CELC, and CNTG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Celcuity, Inc. stock logo
CELC
Celcuity
-$0.95-$0.86+$0.09-$0.86N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
N/AN/AN/AN/AN/A
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/AN/A
Centogene stock logo
CNTG
Centogene
N/AN/AN/AN/AN/A
DermTech, Inc. stock logo
DMTK
DermTech
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
N/A
0.32
0.32
Celcuity, Inc. stock logo
CELC
Celcuity
1.14
6.61
6.61
Centogene stock logo
CNTG
Centogene
N/A
1.02
0.96
DermTech, Inc. stock logo
DMTK
DermTech
N/A
3.53
3.46
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28

Institutional Ownership

CompanyInstitutional Ownership
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
45.84%
Celcuity, Inc. stock logo
CELC
Celcuity
63.33%
Centogene stock logo
CNTG
Centogene
9.94%
DermTech, Inc. stock logo
DMTK
DermTech
20.45%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%

Insider Ownership

CompanyInsider Ownership
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
26.22%
Celcuity, Inc. stock logo
CELC
Celcuity
15.77%
Centogene stock logo
CNTG
Centogene
1.93%
DermTech, Inc. stock logo
DMTK
DermTech
5.10%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fresh2 Group Limited stock logo
ANPC
Fresh2 Group
86970,000715,000Not Optionable
Celcuity, Inc. stock logo
CELC
Celcuity
4037.87 million31.90 millionOptionable
Centogene stock logo
CNTG
Centogene
81027.08 millionN/ANot Optionable
DermTech, Inc. stock logo
DMTK
DermTech
26034.96 million33.18 millionOptionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable

Recent News About These Companies

ENZB - Enzo Biochem Inc Dividends - Morningstar
Enzo Biochem: Fiscal Q3 Earnings Snapshot
Enzo Biochem, Inc. (ENZB)
Enzo Biochem transitions to OTCQX market
OTC Markets Group Welcomes Enzo Biochem, Inc. to OTCQX
Top Research Reports for AbbVie, TJX & Charles Schwab

New MarketBeat Followers Over Time

Media Sentiment Over Time

Fresh2 Group stock logo

Fresh2 Group NASDAQ:ANPC

AnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China.

Celcuity stock logo

Celcuity NASDAQ:CELC

$13.50 -0.13 (-0.92%)
As of 10:48 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Centogene stock logo

Centogene NASDAQ:CNTG

Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany.

DermTech stock logo

DermTech NASDAQ:DMTK

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

$0.32 -0.06 (-14.83%)
Closing price 04/17/2025
Extended Trading
$0.32 0.00 (0.00%)
As of 04/17/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.